These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33826209)

  • 1. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
    Biering-Sørensen T; Minamisawa M; Liu J; Claggett B; Papolos AI; Felker GM; McMurray JJV; Legg JC; Malik FI; Honarpour N; Kurtz CE; Teerlink JR; Solomon SD
    Eur J Heart Fail; 2021 Jun; 23(6):1052-1056. PubMed ID: 33826209
    [No Abstract]   [Full Text] [Related]  

  • 2. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
    Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
    Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
    Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
    Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
    Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
    Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
    Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
    Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].
    Kravchenko I; Rudyk I; Medentseva O
    Georgian Med News; 2021 Sep; (318):165-171. PubMed ID: 34628401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?
    Moin DS; Sackheim J; Hamo CE; Butler J
    Curr Cardiol Rep; 2016 Oct; 18(10):100. PubMed ID: 27568794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
    Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
    J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
    Psotka MA; Teerlink JR
    Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
    Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
    Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omecamtiv Mecarbil in Systolic Heart Failure.
    Komamura K
    N Engl J Med; 2021 May; 384(20):1966-1967. PubMed ID: 34010538
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
    Mack M; Frishman WH
    Cardiol Rev; 2024 Jul-Aug 01; 32(4):378-383. PubMed ID: 36946979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
    Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
    Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omecamtiv Mecarbil in Systolic Heart Failure.
    Bellumkonda L
    N Engl J Med; 2021 May; 384(20):1967. PubMed ID: 34010540
    [No Abstract]   [Full Text] [Related]  

  • 17. Omecamtiv Mecarbil in Systolic Heart Failure.
    Bonapace S; Molon G
    N Engl J Med; 2021 May; 384(20):1967. PubMed ID: 34010539
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    Bernier TD; Buckley LF
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):4-10. PubMed ID: 33165138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
    J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives of a myosin motor activator agent with increased selectivity.
    Nánási P; Komáromi I; Almássy J
    Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.